Ryvu Therapeutics - First ever clinical data from lead assets in 2020
Ryvu Therapeutics (formerly Selvita) is now trading as a standalone biotech after its drug discovery services business was spun out in October 2019. According to the recent Q319 report, R&D progress is on track and 2020 is shaping up to be rather eventful, including expected data readouts from the two clinical trials with lead assets SEL120 and SEL24/MEN1703. Although the trials are early in terms of clinical development (Phase Ib and Phase I/II), they both include secondary endpoints, which will evaluate anti-cancer activity of the compounds. We therefore expect the data readouts to be meaningful catalysts for the share price. Using the same approach and assumptions we developed for the former Selvita’s Innovation segment, our Ryvu valuation is PLN1.08bn or PLN67.4/share.Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company's portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.